List view / Grid view
A placebo is a simulated or otherwise medically ineffectual treatment for a disease or other medical condition intended to make the recipient believe they are receiving something they are not in order to establish whether the true active agent has a noticeable remedy to the ailment it is intended to…
17 February 2016 | By Ingenza Laboratory
Ingenza is using its proprietary inABLE® technology to help develop a robust, versatile platform for the production of cyclic peptides for therapeutic use...
12 February 2016 | By Victoria White
Infliximab is a tumour necrosis factor alpha (TNF-alpha) inhibitor used to treat a range of autoimmune diseases including rheumatoid arthritis and psoriasis...
11 February 2016 | By Quotient Clinical
Quotient Clinical, the Translational Pharmaceutics® company, has announced that it has completed its 100th RapidFACT (Rapid Formulation development And Clinical Testing) program – a significant milestone in the growth of this service, which addresses drug R&D productivity issues...
Tecan has launched a fully automated affinity purification solution for the extraction of large biomolecules, such as proteins, antibodies and antibody-drug conjugates. This set-up takes advantage of the new Thermo Scientific™ MSIA™ Streptavidin EVO microcolumns, which have been specifically designed for use on Tecan’s proven Freedom EVO® platform. In combination…
26 January 2016 | By Victoria White
Humira (adalimumab) is an anti-TNF-α monoclonal antibody which is approved in many regions for the treatment of several inflammatory diseases...
Controlled nucleation is the most significant new development in freeze drying in quite some time.
6 January 2016 | By Andor
This webinar presents real-world methods and examples of how to monitor and assess DNA damage in these cells using the Comet Assay and an insight into the software used to carry out this analysis...
In digital version of Issue #6 2015: Microbiology, Screening, PCR, Continuous Manufacturing, PAT, Regulation, and much more...
6 January 2016 | By Victoria White
Newly presented data from the largest real world study to date demonstrate effectiveness of biosimilar infliximab in patients with inflammatory bowel diseases who have been switched from reference infliximab...
16 December 2015 | By Quotient Clinical
Quotient Clinical, the Translational Pharmaceutics® company, has announced that it has acquired formulation development specialist Co-Formulate Limited...
8 December 2015 | By Victoria White
Sandoz is seeking approval for all indications included in the label of the reference product which is used to treat a range of autoimmune diseases including rheumatoid arthritis and psoriasis...
4 December 2015 | By Victoria White
Amgen believes this submission is the first adalimumab biosimilar application submitted to the EMA and represents Amgen's first biosimilar to be submitted for approval in the EU...
26 November 2015 | By Victoria White
ABP 501 is a biosimilar candidate to AbbVie’s Humira (adalimumab), an anti-TNF-α monoclonal antibody, which is approved in many regions for the treatment of various inflammatory diseases...
18 November 2015 | By Victoria White
The median overall survival for patients assigned personalised peptide vaccine and best-supportive care was almost twice as long as that for patients assigned best-supportive care...
